News Releases
All Releases
View Summary Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
Jan 20, 2016
PDF 19.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
Jan 11, 2016
PDF 23.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
Jan 6, 2016
PDF 22.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
Dec 10, 2015
PDF 38.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Dec 7, 2015
PDF 12.7 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015
Dec 3, 2015
PDF 17.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences
Nov 23, 2015
PDF 17.0 KB Add to Briefcase
View Summary New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
Nov 9, 2015
PDF 24.0 KB Add to Briefcase
View Summary AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
Oct 15, 2015
PDF 21.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2016 and Recent Developments
Sep 9, 2015
PDF 34.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend On Its Series E Convertible Preferred Stock
Sep 8, 2015
PDF 16.7 KB Add to Briefcase
View Summary New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression
Sep 8, 2015
PDF 91.6 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for First Quarter of Fiscal Year 2016 After Market Close on September 9, 2015
Sep 3, 2015
PDF 16.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Data at Annual Immunotherapy and Vaccine Summit (ImVacS) Supporting Ability of Bavituximab to Mediate Anti-Tumor T Cell Responses Across Multiple Tumor Types
Aug 26, 2015
PDF 21.8 KB Add to Briefcase
View Summary AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial
Aug 24, 2015
PDF 21.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2015 Financial Results and Recent Developments
Jul 14, 2015
PDF 40.9 KB Add to Briefcase
View Summary Peregrine to Report Fourth Quarter and Year-End Fiscal Year 2015 Financial Results After Market Close on July 14, 2015
Jul 7, 2015
PDF 15.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab
Jun 25, 2015
PDF 17.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Jun 5, 2015
PDF 23.0 KB Add to Briefcase
View Summary Data Presentations at ASCO Demonstrate the Ability of Peregrine Pharmaceuticals' Bavituximab to Activate Tumor Targeting Immune Cells in PD-L1 Negative NSCLC Tumors
Jun 1, 2015
PDF 31.8 KB Add to Briefcase
Showing 1-20 of 588 Page: 1 2 3 4 5 ... 30  Next 20
Add to Briefcase = add release to Briefcase
Print E-mail